Target-Based De Novo Design
Deterministic
Protein
Engineering.
Eliminating catastrophic sunk costs in early-stage drug discovery. Euclix is an interaction-first, deterministic platform. While the industry screens millions of random keys hoping one fits the lock, we take the lock and cast a key directly inside it. Molecules grow de novo within the target pocket, strictly enforced by immutable physical laws.
Probabilistic Guessing vs. Deterministic Engineering
Traditional Generative Models
Latent Space Guessing
Diffusion and LLM models interpolate structures in abstract latent spaces without grasping physical reality. This probabilistically generates "Ghosts" (overlapping atoms violating Pauli exclusion) or "Levitating Bricks" (high AI scores but zero target interaction), causing catastrophic wet-lab attrition and burning capital.
Interaction-First Euclix
Deterministic Computation
Euclix abandons stochastic generation. We utilize strict Euclidean geometry and continuous thermodynamic physics. Every coordinate is mathematically calculated. We mathematically bound physical realizability in 3D space, delivering molecules engineered to work exactly as computed.
POSITIVE DISCOVERY BIAS
Our engine does not act merely as a judge to reject impossible structures, but as a deterministic finder of realizable solutions. We actively bias our decision trees toward physical existence, targeting geometrically friendly, solvent-accessible pockets to prioritize synthesis-ready candidates over theoretical complexity.
Strategic Target Selection
We map the entire target field to identify shallow, open pockets with clear electrostatic polarity, prioritizing physical viability and geometric simplicity over exotic conformations.
Mathematical Bounds
Trajectories lacking a sterically unblocked escape path are mathematically severed immediately. The engine halts invalid computations to preserve clinical runway and capital.
Solution Instantiation
We limit the search space strictly to domains that possess a global mathematical solution, ensuring that every generated asset is primed directly for laboratory synthesis.
Hyperion Core Architecture
THE DETERMINISTIC ENGINE
Translating thermodynamic potential into robust geometric reality. Use the AI translation tool to distil the commercial value of our core workflow.
Digitalization & Interaction-First
The static receptor is algorithmically transformed into a dense, multi-dimensional physical continuum. We initiate generation via blind seeding exclusively from thermodynamic energy minima hotspots, letting the physical field guide the initial interaction.
Fail-Fast Physical Locks
Coordinates are mathematically constrained by rigid Euclidean boundaries. Instead of guessing and checking, we compute trajectories with a strict fail-fast protocol: if no unblocked path exists, computation halts, preventing structural anomalies from the ground up.
Building the LOVE Protocol
Our mathematical core is fully operational. The primary objective of our Series A is to build the LOVE (Lab Output Verdict Engine) module—an uncompromising in-silico checkpoint integrating ADMET parameters (toxicity, absorption) to filter out unviable candidates before they ever reach the lab.
Engineered in
silico.
Artifacts
Validation
Realizability
Precision
Capital Protection
Equilibrium
Scalable Discovery Infrastructure
Euclix is currently operationalizing its proprietary architecture against rigorous molecular benchmarks. Our system is explicitly designed to aggressively filter the vast parameter space before a single dollar is allocated to wet-lab synthesis.
Processing static receptor structures into multi-dimensional physical continuums to extract viable interaction hotspots.
Deterministically rejecting thousands of probabilistic trajectories that violate Euclidean or thermodynamic constraints.
Delivering geometrically and physically perfect drug scaffolds. These mathematically locked backbones are primed for the next developmental phase: dynamic R-group attachment and final pharmacological calibration.
From Single Binders to Patent Portfolios
Generating an optimal molecule is not the final commercial objective. The true value of the Euclix platform lies in its ability to secure expansive intellectual property rights for our partners.
Our engine natively outputs Markush structures—comprehensive chemical patent formulas defining a core scaffold enriched with specified R-groups across multiple positions.
- Algorithmic protection of chemical space
- Prevention of competitive reverse-engineering
- Direct capitalization of Series A assets
Strategic Expansion Roadmap
The core Hyperion Engine deterministically solves for interaction and geometric bounding. Our immediate milestone and the primary objective of this capitalization is the integration of continuous ADMET constraints and dynamic R-group synthesis directly into the growth gradient.
Dynamic R-Group Synthesis
Scaling the Markush generation architecture to automatically compute and explore vast, synthesizable R-group variations simultaneously across all validated positions.
Continuous ADMET
Embedding strict pharmacological viability rules (absorption, distribution, metabolism, excretion, and toxicity) natively into the algorithmic bounding logic to eliminate late-stage attrition.
Partner Inquiries
For Series A participation, strategic partnerships, or target evaluation requests, please use our secure channel.
System Outage
We are currently experiencing a system outage. Please send your inquiry directly to investors@euclixlabs.com.
THE LAB-GRADE
FOUNDATION
We do not deliver theoretical screen renders. Euclix Labs bounds candidate computation exclusively within real-world physics.
Every molecular scaffold output by our platform is physically and geometrically flawless. Rather than claiming immediate lab-readiness from day one, we guarantee this absolute physical precision as the perfect, unshakable foundation for our next developmental phase—ADMET integration and rigorous in-vitro calibration.
Physics first. Chemistry follows.